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Development and use of recombinant gonadotropin-releasing hormone vaccines
to sterilize cattle: a review
Abstract
A possible alternative to conventional castration methods is the use of vaccines that can be injected in
order to sterilize animals. One promising approach involves the use of a vaccine that causes cattle to
produce an immune response against one of their own reproductive hormones, gonadotropin releasing
hormone (GnRH). Immunization against GnRH results in a decrease in the amount of GnRH circulating
within the animal's blood. Therefore, follicle stimulating hormone (FSH) and luteinizing hormone (LH) are
not stimulated to be released, and, subsequently their levels required for reproductive function.
Experimentation has shown that immunization against GnRH can effectively block reproductive function
in an age-independent manner but has little effect on carcass and growth parameters. However, about
10% of cattle tested do not respond when immunized against GnRH, regardless of dosing regimen.
Further research is needed to improve the efficiency of potential GnRH immunocastration vaccines.; Dairy
Day, 1997, Kansas State University, Manhattan, KS, 1997;
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Dairy Day 1997
DEVELOPMENT AND USE OF RECOMBINANT
GONADOTROPIN-RELEASING HORMONE
VACCINES TO STERILIZE CATTLE: A REVIEW
J. Greer and T. Rozell

Summary

The amino acid sequence of GnRH is common to all mammalian species; pyro-Glu-HisTrp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2.
In
theory, immunizing an animal against GnRH
would elicit endogenous production of antiGnRH antibodies within the animal's body.
These antibodies then would recognize and neutralize endogenously produced GnRH. Immunization of cattle against GnRH would result in
decreased releases of LH and FSH, which, in
turn, would inhibit both testicular and ovarian
development and function.

A possible alternative to conventional castration methods is the use of vaccines that can be
injected in order to sterilize animals. One promising approach involves the use of a vaccine that
causes cattle to produce an immune response
against one of their own reproductive hormones,
gonadotropin releasing hormone (GnRH).
Immunization against GnRH results in a decrease
in the amount of GnRH circulating within the
animal’s blood. Therefore, follicle stimulating
hormone (FSH) and luteinizing hormone (LH)
are not stimulated to be released, and, subsequently, their levels within the body fall below
the levels required for reproductive function.
Experimentation has shown that immunization
against GnRH can effectively block reproductive
function in an age-independent manner but has
little effect on carcass and growth parameters.
However, about 10% of cattle tested do not
respond when immunized against GnRH, regardless of dosing regimen. Further research is
needed to improve the efficiency of potential
GnRH immunocastration vaccines.

Immunization Effects in Heifers
Active immunization of postpubertal beef
heifers, using a vaccine in which GnRH was
conjugated to ovalbumin in complete Freund’s
adjuvant (CFA), was found to induce antibodies
against GnRH at a level that could be detected in
the serum. These same heifers also were found
to have retarded follicular growth, with most
ovaries showing no developing follicles. Pregnancy tests were negative for all immunized
heifers (n=7) at the time of slaughter following
an 8-week breeding period. In contrast, control
animals had a pregnancy rate of 71%. Further
studies found that active immunization of heifers
against similar GnRH constructs resulted in decreases in: the number of receptors for GnRH
within the pituitary, concentrations of LH within
the pituitary, serum progesterone levels, ovarian
weight, uterine weight, follicular development,
and cyclic activity. Multiple immunization of
cyclic beef heifers with GnRH conjugated to
human serum albumin (HSA) and injected in
diethylaminoethyl (DEAE)-dextran adjuvant not
only invoked and maintained anti-GnRH titers,
but also induced a state of anestrus in 29 of 34
heifers for 82.8 ± 6.9 days. This effect was not
dependent on the dose of vaccine.

(Key Words: Gonadotropin Releasing Hormone,
Follicle Stimulating Hormone, Luteinizing
Hormone, Antibody, Immunization.)
Introduction
Gonadotropin releasing hormone (GnRH) is
a neuropeptide synthesized by neurons in the
hypothalamus of the brain. GnRH travels to the
anterior pituitary via the hypothalamic-hypophyseal portal system, where it triggers subsequent
releases of FSH and LH. Released into general
circulation, FSH and LH travel to the gonads,
where they regulate steroid production, folliculogenesis in the ovary, and spermatogenesis in the
testis.
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Research has shown that immunization of
prepubertal heifers against GnRH can delay the
onset of puberty. In 12-month-old heifers receiving two injections of GnRH-HSA in CFA 6
weeks apart, puberty was delayed by an average
of 175 days. A single immunization delayed the
onset of puberty by an average of 112 days. Presumably, these delays were due to decreases in
the secretion of LH and FSH, which ordinarily
stimulate development of the ovaries at the time
of puberty.

Immunization of
Steers and Bulls
Both single- and double-dose administration
of a vaccine consisting of GnRH conjugated to
keyhole limpet hemocyanin (KLH) induced longlasting, high levels of anti-GnRH antibodies. In
these animals, LH concentrations in the serum
were decreased, and immunized bulls also had
retarded testicular growth and decreased
epididymal weight. Immunization also elicited
atrophy of secondary sex organs, including the
prostate and seminal vesicles.

A potential concern about the use of sterilization vaccines is that the immunization ultimately may cause a decline in the release of
certain growth-promoting (anabolic) steroids.
Multiple studies have demonstrated that GnRHimmunization treatments reduced average daily
gain (ADG) in feedlot heifers but did not affect
overall carcass quality. This decreased growth
performance likely was due to reduced estradiol
secretions from acyclic ovaries in GnRH-immunized individuals. This theory is supported by
early research showing ovariectomized heifers as
generally having reduced ADG rates. We should
note, however, that reductions in ADG in both
pre- and postpubertal heifers immunized against
GnRH can be overcome by the use of estradiol
implants. Additionally, these losses in ADG are
less than those seen when heifers become pregnant in the feedlot.

Immunization against GnRH did not affect
the average daily gain in bulls and steers to the
extent seen in heifers, and carcass characteristics
of the immunized animals were comparable to
those of control individuals. Immunization
effects also were not dependent on age.
Considerations for
Vaccine Production
In both bulls and heifers, one problematic
aspect of vaccination against GnRH is the failure
of some treated animals to respond to treatment—overall about 10% of all injected animals
failed to respond to GnRH immunization
whether given one or two injections. Additionally, research has shown that, in order to maintain castration status, repeated dosage is necessary in at least part of the cattle population.
Success rate is dependent on several factors,
including vaccine construct and adjuvant. Current research at Kansas State University is examining the efficiency of various construct/adjuvant
combinations as well as investigating the potential use of an "immunological cocktail", which
would elicit an immunological response against
GnRH, LH, and FSH. The aim of these studies
is to create an efficient, permanent vaccine for
use in both male and female cattle, as well as
satisfying the previously mentioned FDA requirements for vaccines used in food animals.
One of these requirements is that the vaccine
must have an easily identifiable structure that is
perfectly consistent from batch to batch. Current
conjugation techniques (such as those used to

A commercial
anti-GnRH
vaccine,
Vaxtrate®, is currently in use in Australia.
Vaxtrate is a GnRH-ovalbumin conjugate administered in a DEAE-dextran and mineral oil
adjuvant. This vaccine is used primarily to
prevent pregnancy in feedlot cows and heifers at
times when pregnancy is of biological and economical disadvantage (pregnant animals generally gaining less and bringing a lower price per
pound at slaughter). Cattle usually are dosed
twice at an interval of 4 or 16 weeks. Currently,
producers using Vaxtrate® are seeing an 80%
decline in the incidence of pregnancy among
vaccinated animals. Unfortunately, Vaxtrate® is
not available in the United States because of
restrictions placed on vaccine production by the
Food and Drug Administration (FDA).
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produce Vaxtrate®) do not meet these criteria.
Therefore, we are utilizing recombinant DNA
techniques to produce vaccines against GnRH
that will evoke an immune response, as well as
have an identifiable structure (by reading the
DNA sequence of the construct) that is consistent from batch to batch.

Conclusions
Development of a reliable, permanent,
immunological, castration vaccine has obvious
economical and ethical advantages. Castration
via injection would reduce veterinary costs and
man-hours spent castrating and treating domestic
livestock species--this is particularly true for the
females who are not so easily or economically
sterilized. It also provides obvious reduced risks
of infection and complications, not to mention
less stress on the animal. Although immunological castration agents are not yet ready for commercial use, such vaccines likely will be viable
future alternatives to conventional castration
methods.

34

